뉴로핏

380550KOSDAQ

54.8 / 100

Reference Date: 2026-09-08

Financial Score20.5 / 40

News Sentiment21.3 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 16.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Neurophet is a company specializing in medical imaging solutions for neurodegenerative diseases, particularly Alzheimer's, offering products like Neurophet AQUA AD, which assesses Amyloid-Related Imaging Abnormalities (ARIA) severity. The company holds international certifications such as CE, FDA 510K, and GMP, and provides Clinical Research Organization (CRO) services to support medical device development.

Number of Employees

139people

Average Salary

58.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

4.43Industry Average 1.200.0Point

3.7x industry avg (risky)

ROE

—Industry Average 8.003.5Point

Debt Ratio

2.55Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 5.0 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.5 / 3

ROE Trend

2.0 / 4

Detailed News Sentiment

4 totalPositive 4Neutral 0Negative 0Average Sentiment Score 85

Positive
뉴로핏, 美 엘리베이트 클리닉에 AI 뇌질환 솔루션 공급
뉴로핏의 AI 뇌질환 솔루션이 미국 주요 신경계 전문 클리닉에 공급되어 글로벌 시장 진출에 긍정적 영향을 미칠 것으로 예상됩니다.
Positive
"뇌질환 시장 확대"…뉴로핏, 美에 '의료AI' 공급
뉴로핏의 미국 의료기관 공급 계약 확보로 뇌질환 시장 확대 기대.
Positive
뉴로핏, AI로 뇌 건강 확인하는 서비스 확대
뉴로핏이 AI 기반 뇌 건강 서비스 확대를 통해 헬스케어 시장 진출을 강화함으로써 긍정적인 투자 전망을 제공합니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 7,060Won52-week high 36,70052-week low 6,200

1-month return0.0Point

1m -16.75% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-14